<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02622685</url>
  </required_header>
  <id_info>
    <org_study_id>DW_P10292002P</org_study_id>
    <nct_id>NCT02622685</nct_id>
  </id_info>
  <brief_title>A Multiple Dose Study of DWP10292 and UDCA in Healthy Male Subjects</brief_title>
  <official_title>A Dose Block-randomized, Double-blind, Placebo Controlled, Multiple Dosing, Dose-escalation Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of DWP10292 and Ursodeoxycholic Acid in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety, tolerability, pharmacokinetics and
      pharmacodynamics of DWP10292 and UDCA in healthy male volunteers after multiple-dosing.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is dose block-randomized, double-blind, placebo controlled, multiple-dosing, dose
      escalation clinical trial to investigate the safety, tolerability and pharmacokinetic
      characteristics of DWP 10292 after oral administration in healthy male subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of Pharmacokinetics</measure>
    <time_frame>Multiple blood sample will be collected for 24 hours after last dosing in each of the periods</time_frame>
    <description>Peak Plasma Concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite of Pharmacokinetics</measure>
    <time_frame>Multiple blood sample will be collected for 24 hours after last dosing in each of the periods</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite of Pharmacokinetics</measure>
    <time_frame>Multiple blood sample will be collected for 24 hours after last dosing in each of the periods</time_frame>
    <description>Mean residence time (MRT)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite of Pharmacokinetics</measure>
    <time_frame>Multiple blood sample will be collected for 24 hours after last dosing in each of the periods</time_frame>
    <description>Accumulation index</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>[Safety &amp; tolerability] Incidence of adverse events related with drug</measure>
    <time_frame>4 weeks</time_frame>
    <description>Adverse events, Physical exam, Vital sign, laboratory (CBC, chemistry, U/A etc)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>DWP10292</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: DWP10292 DWP10292 tablets, oral administration, multiple administration
Arms: DWP10292</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DWP10292 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: Placebo Placebo tablets, oral administration, multiple administrations
Arms: Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ursodeoxycholic acid (UDCA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Ursodeoxycholic acid (UDCA) UDCA tablets, oral administration, multiple administrations
Arms: Ursodeoxycholic acid (UDCA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ursodeoxycholic acid (UDCA) Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: Placebo Placebo tablets, oral administration, multiple administrations
Arms: Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWP10292</intervention_name>
    <description>Drug: DWP10292 tablets, oral administration, multiple administration</description>
    <arm_group_label>DWP10292</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWP10292 Placebo</intervention_name>
    <description>Placebo tablets, oral administration, multiple administrations</description>
    <arm_group_label>DWP10292 Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ursodeoxycholic acid (UDCA)</intervention_name>
    <description>Drug: Ursodeoxycholic acid (UDCA) tablets, oral administration, multiple administration</description>
    <arm_group_label>Ursodeoxycholic acid (UDCA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UDCA Placebo</intervention_name>
    <description>Placebo tablets, oral administration, multiple administrations</description>
    <arm_group_label>Ursodeoxycholic acid (UDCA) Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A subject who provided written informed consent to participate in this study and
             cooperative with regard to compliance with study related constraints

          -  Healthy adult male subjects aged 19 to 45 years

          -  The subject has a Body weight ≥ 60 kg and &lt; 90 kg and Body Mass Index(BMI) ≥ 18.5
             kg/m2 and &lt; 27.0 kg/m2

          -  A Subject who was judged to be healthy by the investigator to participate in this
             study based on screening results (according to standard reference index updated
             recently)

        Exclusion Criteria:

          -  A subject with sign or symptoms or previously diagnosed disease of liver (viral
             hepatitis), digestive system, cardiovascular, kidney, respiratory, endocrinology,
             neurology, immune system, hematology, and psychology function or other significant
             diseases and history or suspicion of current drug abuse and alcohol abuse

          -  A subject who shows vital signs with the number of systolic blood pressure of ≥140
             mmHg or ≤100 mmHg, and the number of diastolic blood pressure of ≥90mmHg or ≤60mmHg

          -  A subject who donates his blood (whole blood donation within last 2 months or plasma
             donation within last 1 month) or received a blood transfusion within last 1 month

          -  Subject who has taken other clinical or licensed medication from another clinical
             trial within an 3-month period prior to the first administration of the study
             medication (The last administration of the medication is considered as an end point of
             the previous clinical trial)

          -  Subject who smokes an average of 10 cigarettes/day and is unable to quit smoking
             during the clinical trial
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2015</study_first_submitted>
  <study_first_submitted_qc>December 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2015</study_first_posted>
  <last_update_submitted>June 1, 2016</last_update_submitted>
  <last_update_submitted_qc>June 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ursodeoxycholic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

